Please use this identifier to cite or link to this item:
Title: Targeted therapy for metastatic colorectal cancer.
Austin Authors: Price, Timothy J;Tang, Monica;Gibbs, Peter;Haller, Daniel G;Peeters, Marc;Arnold, Dirk;Segelov, Eva;Roy, Amitesh;Tebbutt, Niall C ;Pavlakis, Nick;Karapetis, Chris;Burge, Matthew;Shapiro, Jeremy
Affiliation: Medical Oncology, The Queen Elizabeth Hospital, Woodville, and University of Adelaide, Adelaide, Australia
Medical Oncology, NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia
Medical Oncology, Western Hospital, Melbourne, Australia
Medical Oncology, Walter and Eliza Hall Institute, Melbourne, Australia
Medical Oncology, Abrahamson Cancer Centre at the Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
Medical Oncology, University Hospital Antwerp, Edegem, Belgiumg Asklepios Tumorzentrum Hamburg, Hamburg, Germany
Medical Oncology, Asklepios Tumorzentrum Hamburg, Germany
Medical Oncology, Monash University School of Clinical Sciences at Monash Health, Monash Medical Centre, Clayton, Australia
Medical Oncology, Flinders Centre for Innovation in Cancer, Bedford Park, Australia
Medical Oncology, Flinders University, Bedford Park, Australia
Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia
Medical Oncology, Royal North Shore Hospital, St Leonards, Australia
Medical Oncology, Royal Brisbane Hospital, Brisbane, Australia
Medical Oncology, Cabrini Hospital and Monash University, Melbourne, Australia
Issue Date: Oct-2018 2018-08-03
Publication information: Expert review of anticancer therapy 2018; 18(10): 991-1006
Abstract: Outcomes in metastatic colorectal cancer are improving, with better understanding and use of targeted therapies. Areas covered: A review of the literature and recent conference presentations was undertaken on the topic of systemic treatment of metastatic colorectal cancer. This article reviews the current evidence for targeted therapies in advanced colorectal cancer, including up-to-date data regarding anti-epidermal growth factor receptor (EGFR) and anti-vascular endothelial growth factor (VEGF) agents, the relevance of primary tumor location and novel subgroups such as BRAF mutated, HER2 amplified, and mismatch-repair-deficient cancers. Expert commentary: EGFR-targeted and VEGF-targeted antibodies are now routinely incorporated into treatment strategies for metastatic colorectal cancer (mCRC). The use of EGFR-targeted antibodies should be restricted to patients with extended RAS wild-type profiles, and there is evidence that they should be further restricted to patients with left-sided tumors. Clinically, mCRC can be divided into subgroups based on RAS, BRAF, HER2, and MMR status, each of which have distinct treatment pathways.
DOI: 10.1080/14737140.2018.1502664
PubMed URL: 30019590
Type: Journal Article
Subjects: Colorectal
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Nov 30, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.